ERBB2 and breast cancer: In addition, several other diverse combinations of anti-HER2 agents plus endocrine therapy/CDK 4/6 inhibitors/immunotherapy/other targeted agents are currently being tested in early-phase clinical trials, thus emphasizing the fervent interest on this dawning breast cancer subtype4.